PURPOSE: Brown adipose tissue (BAT) has transformed from an interfering tissue in oncological (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET) to an independent imaging research field. This review takes the perspective from the imaging methodology on which human BAT research has come to rely on heavily. METHODS: This review analyses relevant PubMed-indexed publications that discuss molecular imaging methods of BAT. In addition, reported links between BAT and human diseases such as obesity are discussed, and the possibilities for imaging in these fields are highlighted. Radiopharmaceuticals aiming at several different biological mechanisms of BAT are discussed and evaluated. RESULTS: Prospective, dedicated studies allow visualization of BAT function in a high percentage of human subjects. BAT dysfunction has been implicated in obesity, linked with diabetes and associated with cachexia and atherosclerosis. Presently, (18)F-FDG PET/CT is the most useful tool for evaluating therapies aiming at BAT activity. In addition to (18)F-FDG, other radiopharmaceuticals such as (99m)Tc-sestamibi, (123)I-metaiodobenzylguanidine (MIBG), (18)F-fluorodopa and (18)F-14(R,S)-[(18)F]fluoro-6-thia-heptadecanoic acid (FTHA) may have a potential for visualizing other aspects of BAT activity. MRI methods are under continuous development and provide the prospect of functional imaging without ionizing radiation. CONCLUSION: Molecular imaging of BAT can be used to quantitatively assess different aspects of BAT metabolic activity.
PURPOSE: Brown adipose tissue (BAT) has transformed from an interfering tissue in oncological (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET) to an independent imaging research field. This review takes the perspective from the imaging methodology on which human BAT research has come to rely on heavily. METHODS: This review analyses relevant PubMed-indexed publications that discuss molecular imaging methods of BAT. In addition, reported links between BAT and human diseases such as obesity are discussed, and the possibilities for imaging in these fields are highlighted. Radiopharmaceuticals aiming at several different biological mechanisms of BAT are discussed and evaluated. RESULTS: Prospective, dedicated studies allow visualization of BAT function in a high percentage of human subjects. BAT dysfunction has been implicated in obesity, linked with diabetes and associated with cachexia and atherosclerosis. Presently, (18)F-FDG PET/CT is the most useful tool for evaluating therapies aiming at BAT activity. In addition to (18)F-FDG, other radiopharmaceuticals such as (99m)Tc-sestamibi, (123)I-metaiodobenzylguanidine (MIBG), (18)F-fluorodopa and (18)F-14(R,S)-[(18)F]fluoro-6-thia-heptadecanoic acid (FTHA) may have a potential for visualizing other aspects of BAT activity. MRI methods are under continuous development and provide the prospect of functional imaging without ionizing radiation. CONCLUSION: Molecular imaging of BAT can be used to quantitatively assess different aspects of BAT metabolic activity.
Authors: G H E J Vijgen; N D Bouvy; G J J Teule; B Brans; J Hoeks; P Schrauwen; W D van Marken Lichtenbelt Journal: J Clin Endocrinol Metab Date: 2012-04-24 Impact factor: 5.958
Authors: O Petrák; D Haluzíková; P Kaválková; B Štrauch; J Rosa; R Holaj; A Brabcová Vránková; D Michalsky; M Haluzík; T Zelinka; J Widimsky Journal: J Clin Endocrinol Metab Date: 2013-02-22 Impact factor: 5.958
Authors: Alexander Bartelt; Oliver T Bruns; Rudolph Reimer; Heinz Hohenberg; Harald Ittrich; Kersten Peldschus; Michael G Kaul; Ulrich I Tromsdorf; Horst Weller; Christian Waurisch; Alexander Eychmüller; Philip L S M Gordts; Franz Rinninger; Karoline Bruegelmann; Barbara Freund; Peter Nielsen; Martin Merkel; Joerg Heeren Journal: Nat Med Date: 2011-01-23 Impact factor: 53.440
Authors: Anouk A J J van der Lans; Joris Hoeks; Boudewijn Brans; Guy H E J Vijgen; Mariëlle G W Visser; Maarten J Vosselman; Jan Hansen; Johanna A Jörgensen; Jun Wu; Felix M Mottaghy; Patrick Schrauwen; Wouter D van Marken Lichtenbelt Journal: J Clin Invest Date: 2013-07-15 Impact factor: 14.808
Authors: M P Coleman; B Rachet; L M Woods; E Mitry; M Riga; N Cooper; M J Quinn; H Brenner; J Estève Journal: Br J Cancer Date: 2004-04-05 Impact factor: 7.640
Authors: José V Pardo; Robert C Larson; Rachel J Spencer; Joel T Lee; Jeffrey D Pasley; Carolyn J Torkelson; Alice A Larson Journal: Clin J Pain Date: 2019-05 Impact factor: 3.442
Authors: Srihari C Sampath; Srinath C Sampath; Miriam A Bredella; Aaron M Cypess; Martin Torriani Journal: Radiology Date: 2016-07 Impact factor: 11.105
Authors: Andrew M Kim; Brendan T Keenan; Nicholas Jackson; Eugenia L Chan; Bethany Staley; Drew A Torigian; Abass Alavi; Richard J Schwab Journal: Am J Respir Crit Care Med Date: 2014-06-01 Impact factor: 21.405
Authors: Salih Ozguven; Tunc Ones; Yusuf Yilmaz; H Turgut Turoglu; Nese Imeryuz Journal: Eur J Nucl Med Mol Imaging Date: 2015-08-19 Impact factor: 9.236